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Abstract
Zygomycoses are severe angio-invasive fungal infections that develop in immunocompromised and diabetic patients. Any episode of
sinusitis not responding to short-term antibacterial therapy should evoke the diagnosis of zygomycosis in the latter population,
especially in cases of a surrounding necrotic area. Appropriate diagnosis is obtained after careful direct examination of the sample and
culture. Current therapy underscores the need to control glycaemia and acidosis in addition to the need for urgent administration of
high-dose liposomal amphotericin B in combination with extensive surgery.
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Introduction
Zygomycosis is a group of severe angio-invasive infections
caused by common saprophyte ﬁlamentous fungi, the zygo-
mycetes. These ubiquitous fungi can cause opportunistic
infections with high lethality in diabetic patients. Whatever
the route of contamination (inhalation of airborne spores,
ingestion, or direct skin inoculation), the hyphae invade
blood vessels, causing tissue infarction and necrosis [1–3].
In healthy individuals, innate immunity is sufﬁciently efﬁcient
to prevent infection, except in cases of massive contamina-
tion after traumatic inoculation of contaminated soil [4,5].
Patients with phagocytic dysfunctions due to neutropenia
or ketoacidosis, or patients with high iron serum concen-
trations, are at high risk of developing zygomycosis [3].
These underlying conditions can inﬂuence the clinical pre-
sentation and outcome [1]. The rhinocerebral form of
zygomycosis is the most frequently reported in the diabetic
population.
In this article, we review data regarding diabetes-associ-
ated zygomycosis.
Epidemiology
The incidence of zygomycosis is seemingly increasing [6,7], at
least in the population of patients with haematological malig-
nancies. Several explanations are possible: longer survival of
individuals with severe haematological malignancies, increased
awareness of the infection on the part of physicians, improved
diagnosis, and the prolonged use of voriconazole as prophy-
lactic or empirical treatment in bone marrow transplant recipi-
ents [6,8,9]. Among 929 reported cases of zygomycosis in the
literature, Roden et al. [4] showed that diabetic patients repre-
sented 36% of the total population, with type 1 diabetes repre-
senting 20% of the total number. Ketoacidosis was found in
48% of patients with type 1 diabetes and 34% of those with
type 2 diabetes. The same authors also reported a decreased
number of diabetic patients developing zygomycosis over time
[4], a ﬁnding that is in marked contrast to the increased preva-
lence of diabetes in the world [10]. Such a decreased incidence
of diabetes-associated zygomycosis led Kontoyiannis to specu-
late that the widespread use of statins in the diabetic popula-
tion, at least in the Western world, might have resulted in the
decreased rate of zygomycosis in this population [11]. Indeed,
lovastatin has in vitro and in vivo activity against zygomycetes/
zygomycosis [12,13], and statins are known immunomodula-
tors that could help in the defence against zygomycosis [14].
However, through a collaboration between French public
health authorities (Institut National de Veille Sanitaire) and
the National Reference Centre for Mycoses and Antifungals,
a population-based study of medical records of zygomycosis
cases reported in France from 1997 to 2006 was performed
to estimate the incidence of zygomycosis at the country
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level. Eighty-four per cent of diabetic patients were aged
more than 44 years, and a 9% yearly increase in the annual
incidence rate of zygomycosis in the diabetic population was
observed [15].
It is of note that, in a recent literature review of 157
zygomycosis cases occurring in children (0–18 years), diabe-
tes mellitus was found in 15% (type 1 = 13%) and ketoacido-
sis in 10% [14,16].
A recent paper from a tertiary-care centre in North India
also emphasized the emergence of diabetes-associated zygo-
mycosis in the developing world. Indeed, 131 of 178 cases
were observed in uncontrolled diabetic patients (73.6%), and,
more importantly, zygomycosis led to a diagnosis of diabetes
in 56 cases (42.7% of diabetes cases) [17]. A recent study
collected 41 cases of rhino-orbital and rhino-orbito-cerebral
zygomycosis between 1994 and 2006 in California. The
authors reported that 83% of the patients had diabetes (only
59% had a known history of diabetes mellitus), and only 21%
of 14 patients with corticosteroid-induced diabetes were
receiving medication for diabetes [18]. Finally, among other
high-risk populations that may develop zygomycosis, the
presence of diabetes also inﬂuences the occurrence of the
fungal infection. Indeed, during a prospective study involving
patients with leukaemia and/or bone marrow transplantation,
diabetes was found as an independent risk factor for the
occurrence of zygomycosis [19]. In addition, Singh et al.
recently showed that the presence of diabetes also signiﬁ-
cantly inﬂuenced the occurrence of zygomycosis in solid
organ transplant patients [20].
Pathophysiology of Diabetes-associated
Zygomycosis
Macrophages and neutrophils represent the major host cel-
lular defences against zygomycetes. In addition to the neu-
trophil dysfunction classically reported during diabetes [21],
low serum pH diminishes the phagocytic effect of macro-
phages and the chemotactic and oxidative burst of neu-
trophils, modiﬁes the transferrin system (leading to more
unbound iron, which is then utilizable by zygomycetes), and
reduces the serum inhibitory activity against Rhizopus
[21–24]. It is of note that a reduced neutrophil-related
inﬂammatory response against Rhizopus has been described
in diabetic rabbits [25]. A speciﬁc pathogenic role of hyper-
glycaemia itself has also been documented, in reducing the
ability of macrophages to prevent Rhizopus germination
[26]. In addition, ketones have been shown to alter the
permeability of the blood–brain barrier [27], and this might
contribute to the magnitude of cerebral involvement during
diabetes-associated zygomycosis. Finally, it has been shown
that diabetic mice are susceptible to an intra-ethmoidal
challenge with 106 Rhizopus oryzae spores, with 90% of dia-
betic mice dying (77% within 4 days) with viable fungi in
brain and lungs, contrasting with the absence of death in
control mice [23].
Clinical Presentation of Zygomycosis in
Diabetic Patients
Among the diabetic population described by Roden et al., 66%
presented with sinusitis, most often with cerebral (43%) or
orbital (15%) involvement. Interestingly, no localized cerebral
infection was observed in the diabetic population, suggesting
that there is a nasal portal of entry in these patients. Lung
involvement and cutaneous involvement were reported in
16% and 10% of cases, respectively. In another study, among
179 patients with sinus zygomycosis, 70% presented with
ketoacidosis [28]. In the study from Reed et al., 83% of 41
patients with rhinocerebral zygomycosis were diabetics [18].
Outcome of Diabetes-associated
Zygomycosis
The overall mortality of diabetic patients with zygomycosis
reported in the literature is as high as 44% [4], and the sub-
sequent death rate in children with ketoacidosis and zygomy-
cosis is 25% [16]. However, more recent data from France
have shown a case-fatality rate at hospital discharge of 9.2%
in diabetic patients that remained stable over a 10-year per-
iod [15]. In cases of combination therapy using amphoteri-
cin B (AmB) and surgery, the survival rate was 79.6% in an
Indian study involving mostly diabetic patients [17]. Overall,
the case-fatality rate of patients with the rhinocerebral form
decreases from 70% in patients treated with antifungals alone
to 14% in patients who receive antifungals combined with
surgical treatment [29].
Contribution of Experimental Models to
the Management of Diabetes-associated
Zygomycosis
Most experimental therapeutic data have been obtained in
the diabetic ketoacidotic mouse model of disseminated zygo-
mycosis designed by Ibrahim et al. from UCLA. In a ﬁrst
study, the investigators compared liposomal AmB (LAmB)
(2, 5 and 7.5 mg/kg twice daily ) with AmB (0.5 mg/kg twice
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daily). High-dose LAmB increased the median survival time
and overall survival, whereas the groups receiving low-dose
LAmB and AmB had a survival time similar to that of con-
trols. Thus, in this model, high-dose LAmB was more effec-
tive than AmB [30]. The same group then compared LAmB
and AmB lipid complex (ABLC) (7.5 and 15 mg/kg per day).
In their model, LAmB [15] increased survival as compared to
ABLC (7.5 and 15 mg/kg per day), and LAmB, but not ABLC
(7.5 mg/kg per day), reduced the cerebral fungal burden.
Thus, LAmB does better than ABLC during experimental
diabetes-associated zygomycosis [31]. The contribution of
caspofungin was also examined. The authors showed that
R. oryzae had an FKS gene, that caspofungin inhibited glucane
synthase activity in crude R. oryzae membrane preparations,
and, ﬁnally, that caspofungin at a low dose (0.5 mg/kg twice
daily) improved the survival of mice infected with a small
inoculum [32]. Interestingly, the same group also investigated
the potential role of combination therapy with ABLC (5 mg/
kg per day) ± caspofungin (1 mg/kg per day). Combination
therapy improved survival is compared to monotherapy,
whereas the combination arm failed to improve organ clear-
ance. In this model, the prophylactic antifungal combination
was not more effective than monotherapy [33].
In addition, the impact of iron chelation has been studied
during diabetes-associated zygomycosis. Deferiprone exhib-
ited fungistatic activity at 24 h and fungicidal activity at 48 h
against R. oryzae, with an efﬁcacy equivalent to that of LAmB
in mice when measured by survival rate and brain fungal bur-
den. In this model, free iron reversed protection. Another
recent chelator, deferasirox (Exjade), was also effective (as
measured by time to death/fungal burden) in ketoacidotic
mice, was synergistic with LAmB, and increased the inﬂam-
matory response [34,35]. From a clinical perspective, in a
preliminary case report, a 7-day oral course (15 mg/kg
per day) of deferasirox as salvage therapy was effective in a
diabetic patient with rhinocerebral zygomycosis [36].
Therapeutic Management of
Diabetes-associated Zygomycosis
Prospective therapeutic trials on the management of zygomy-
cosis have not been reported. Most new antifungals, includ-
ing voriconazole, are not active against zygomycetes [37],
whereas polyenes and posaconazole display, at least in vitro,
activity against zygomycetes [38]. Posaconazole has limited
activity against certain zygomycetes. In a murine model of
zygomycosis, posaconazole showed partial efﬁcacy against
Mycocladus corymbifer and a dose-dependent response effect
in mice infected with Rhizopus microsporus [38].
Following the demonstration of posaconazole activity
against zygomycetes in vitro and its potential efﬁcacy in
experimentally infected animals, the clinical potential of po-
saconazole in patients with zygomycosis was retrospectively
evaluated in two studies in which the drug was given as
second-line therapy in individuals who had been treated
with other antifungals that were not tolerated or had an
insufﬁcient effect. Response rates of 60% in 91 patients and
79% in 24 patients, respectively, were reported [39,40]. It
should be remembered that posaconazole can only be
administered orally and carries the risk of drug–drug inter-
actions, as is typical for the azole class of antifungal com-
pounds [41]. Moreover, steady-state plasma levels are
obtained only after 7–10 days of treatment [42]. Without
representative data on ﬁrst-line treatment, we consider that
posaconazole should not be used as ﬁrst-line treatment of
zygomycosis. If the intravenous formulation of posaconazole
becomes available, then a clinical trial comparing intrave-
nous posaconazole with LAmB could be performed, and
could provide potentially interesting perspectives on the
management of zygomycosis.
The options and limitations of AmB deoxycholate (AmBD)
and LAmB as ﬁrst-line treatment for zygomycosis have been
assessed in several retrospective analyses. A recent large
retrospective survey, which included all cases of zygomyco-
sis that had been described in the literature, reported a
61% survival rate for AmBD as compared with 69% for
LAmB [43]. Two other retrospective studies evaluated the
efﬁcacy and safety of the alternative lipid formulations of
AmB in the setting of second-line treatment of zygomy-
cosis. The series of patients treated with ABLC at a dose
of 5 mg/kg per day was characterized by a wide variety of
risk factors, and showed a 75% response rate for this drug
[44]. AmB colloidal dispersion given in doses between 2
and 6 mg/kg per day gave an objective response in 60% of
cases [45].
A recent study retrospectively compared patients treated
with polyene for rhino-orbito-cerebral mucormycosis with
those treated with a polyene–caspofungin combination [18].
The success rate was higher for patients treated with the
combination. It is of note that 22 patients were treated with
AmB lipid complex, which exhibits reduced central nervous
system penetration in the rabbit model in comparison with
AmB or LAmB [46].
Another recent study reported an increased mortality rate
in haematology patients with zygomycosis for whom AmB-
based front-line therapy was delayed (treatment initiation
‡6 days after diagnosis resulted in a two-fold increased
mortality rate) [47], and extrapolation of these data to the
diabetic population seems acceptable.
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In summary, lipid derivatives of AmB are probably more
effective and better tolerated than AmBD in the treatment
of zygomycosis. Whether higher dosages of LAmB would be
of beneﬁt for this indication remains unknown. Indeed, the
area under the curve of LAmB is maximal at a dose rate of
10 mg/kg per day; at this level, the drug can saturate mono-
nuclear cells and allow greater accumulation of AmB in the
lungs, which are a major target of infection by the agents of
zygomycosis [48]. Moreover, high doses of LAmB effected a
clinical response in patients who failed to respond to con-
ventional dosages [49,50]. In an attempt to provide an answer
to the question of adequate dosing, we started in May 2007 a
prospective national phase II multicentre study (‘Ambizygo’
trial) in France to evaluate the maximally effective and toler-
ated dose of LAmB (up to 10 mg/kg per day) as ﬁrst-line
treatment for zygomycosis in 27 adults and children. In addi-
tion, LAmB + iron chelation vs. LAmB is currently under
investigation in patients with zygomycosis in the USA.
Conclusions
In conclusion, diabetes-associated zygomycosis is encoun-
tered with a variable epidemiology, according to country. Its
pathophysiology remains incompletely understood, and dia-
betes now represents a signiﬁcant risk factor in previously
immunosuppressed patients. Rhinocerebral mucormycosis
needs early recognition and strict control of glycaemia/pH,
and beneﬁts from high-dose LAmB and aggressive surgery
followed by long-term oral posaconazole therapy.
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